Ryan Patrick Quinn Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 18 Harbor Cir, Centerport, NY 11721 Phone: 631-418-7634 |
Naomi R Ulrich Ma Occupational Therapist Pc Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4 Haven Ct, Centerport, NY 11721 Phone: 631-848-5002 |
Mrs. Leigh Ann Castellano, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3 Morahapa Rd, Centerport, NY 11721 Phone: 631-261-1363 |
Mrs. Diana E. Keegan, OTR Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 9 Quay Ct, Centerport, NY 11721 Phone: 631-754-6414 |
Lisa Miske, M.S., O.T.R./L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 27 Cranbrook Ct, Centerport, NY 11721 Phone: 631-902-5597 |
News Archive
Terraboost - creator of the patent pending combination hand sanitizing display/dispenser - announced a new program today to provide complimentary touch-free hand sanitizing displays to businesses worldwide, helping people around the globe mitigate risk related to H1N1 swine flu and other disease-causing bacteria.
Onyx Pharmaceuticals, Inc. announced today that the company has begun enrollment in the ENDEAVOR trial, a Phase 3 trial evaluating Kyprolis in combination with dexamethasone, versus bortezomib with dexamethasone in patients with relapsed multiple myeloma.
Swimsuit season is almost upon us. For most of us, the countdown has begun to lazy days lounging by the pool and relaxing on the beach. However, for some of us, the focus is not so much on sunglasses and beach balls, but how to quickly shed those final five or ten pounds in order to look good poolside. It is no secret that dieting can be challenging and food cravings can make it even more difficult.
Radiology and cardiovascular researchers from the Medical University of South Carolina in Charleston, S.C., today presented new data that shows the risk of cancer from exposure to radiation during computed tomography for cardiovascular disease has been overstated and that new estimates are several times lower than previously published conclusions.
Oncotarget Volume 11, Issue 11 reported that in this preclinical study, we characterized the binding affinity and selectivity of quizartinib, a small-molecule inhibitor of FLT3, and AC886, the active metabolite of quizartinib, compared with those of other FLT3 inhibitors.
› Verified 9 days ago